Oncology Topic Homepage

CLL Knowledge Centre

,CLL KC

Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world.1,2 In the UK, CLL accounts for 1% of all new cancer cases and 38% of all leukaemias.3

The new CLL Knowledge Centre provides healthcare professionals with important information to aid the treatment and management of patients with the disease. Content is arranged within three main areas: ‘Disease awareness’, ‘Events’ and ‘Resources’.

Healthcare professionals will find sections on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment, management, an upcoming events calendar and useful external links.

We are conducting a short survey regarding educational needs of healthcare professionals in relation to chronic lymphocytic leukaemia (CLL) and other haematological malignancies.
The questions will take approximately 5-10 minutes of your time to complete and your input will be much appreciated.

  1. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013 Nov 28;122(23):3723-34.
  2. Gibson J, Iland HJ, Larsen SR, Brown CM, Joshua DE. Leukaemias into the 21st century. Part 2: the chronic leukaemias. Intern Med J. 2013 May;43(5):484-94.
  3. CRUK (Cancer Research UK) 2014: Chronic lymphocytic leukaemia (CLL) incidence statistics. Updated June 2014. Accessed 25.03.15. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll/incidence

Prostate Cancer Learning Hub

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.

     

Soft Tissue Sarcoma

Soft Tissue Sarcoma

Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.

Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1

For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.

Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.


References

  1. . Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.

Anti-Infectives Knowledge Network CDI

,AIKN CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infections (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the area of anti-infectives.

Recent content updates include:

  • Presentation slides from recent congresses including ECCMID, EBMT and ISICEM 2015
  • News articles from key industry thinkers located within the ‘CDI perspectives’ section
  • An animation sequence showing gut microflora and the effects of antibiotics on CDI
  • Opportunity to participate in the second round of the largest ever clinician consensus report through completing a questionnaire. Subsequent recommendations will be made based on the data collected from this questionnaire

Please remember to return often to read updated news, clinical insights, and essential information from the latest congresses.

May 2015 MYC/15/0020/EUb

Anti-Infectives Knowledge Network IFI

,AIKN IFI

The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with particular focus on invasive fungal infections.

This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material (e.g. presentation slides) from major medical events.

The latest update to the AIKN-IFI is a summary of recent ESCMID-led recommendations into the prevention and management of infections in solid organ transplantation. These new recommendations are available in the guidelines section.

May 2015 MYC/15/0020/EUb

Clinical Case Studies

Hypersensitivity Pneumonitis

Respiratory Medicine & Allergy: Non granuloma interstitial lung disease

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Boris Lams, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 49-year-old Cypriot woman was referred with a nine-month history of gradually increasing breathlessness and a dry cough. She was breathless at 100 yards.

Mediastinal Mass: Bronchogenic Cyst

Respiratory Medicine & Allergy: Lung Cancer

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK

Case History
A 24-year-old woman was seen in the chest clinic with an eight-week history of cough with occasional sputum, fever and malaise. She also described an occasional nagging pain under her sternum and palpitations.

Latest News

Medical Videos

In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
Eribulin Trial Success
Eribulin Trial Success
New Developments in the Treatment of Breast Cancer
New Developments in the Treatment of Breast Cancer
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
An Overview of Pancreatic NET and the Available Treatments
An Overview of Pancreatic NET and the Available Treatments
Surviving Advanced Breast Cancer
Surviving Advanced Breast Cancer
An Animation Explaining the Development of Lymphoma
An Animation Explaining the Development of Lymphoma
Cancer Vaccines- Dr. Kelvin Lee
Cancer Vaccines- Dr. Kelvin Lee
HPV Vaccine
HPV Vaccine

Recent Drug Updates

Medical Journal Abstracts on Oncology

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.

Sat 18 Jul 2015 -  Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.

Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in ...

Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.

Fri 17 Jul 2015 -  Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.

Background: Dysregulation of circulating miR-328 has been identified in several tumors and is associated with prognosis of patients. However, the expression pattern of miR-328 and the impact on ...

Medical Images

Sarcoidosis - chest radiograph
Sarcoidosis - chest radiograph
Bronchogenic cyst
Bronchogenic cyst
Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)
Amiodarone Pulmonary Toxicity
Amiodarone Pulmonary Toxicity
Sarcoidosis - radiograph showing interstitial shadowing
Sarcoidosis - radiograph showing interstitial shadowing
Pulmonary nodule
Pulmonary nodule
Hematoxylin and eosin stain
Hematoxylin and eosin stain
Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis

Clinical Guidelines

Suspected cancer: recognition and referral

Jun 2015

This guideline updates and replaces NICE clinical guideline CG27 (published June 2005). It offers..

... evidence-based advice on the recognition of and referral for suspected cancer in children, young people and adults.

This guideline covers the recognition and selection for referral or investigation in primary care of people of all ages, including children and young people, who may have cancer. Although we have used the terms 'men' and 'women' for recommendations on gender-related cancers, these recommendations also extend to people who have changed or are in the process of changing gender, and who retain the relevant organs.

The guideline aims to help people understand what to expect if they have symptoms that may suggest cancer. It should also help those in secondary care to understand which services should be provided for people with suspected cancer. Finally, these recommendations are recommendations, not requirements, and they are not intended to override clinical judgement.

The recommendations in this guideline have been organised into 3 separate sections to help clinicians find the relevant information easily. In the first, the recommendations are organised by cancer site. There is a section covering patient support, safety netting and the diagnostic process. Then, for those wanting to find recommendations on specific symptoms and primary care investigations, the recommendations are in a section organised by symptoms and investigation findings.

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index

Jun 2015

NICE has not recommended the PROGENSA PCA3 assay and the Prostate Health Index for use in people..

... having investigations for suspected prostate cancer, who have had a negative or inconclusive transrectal ultrasound prostate biopsy. The PCA3 assay is diagnostic test that detects the level of prostate cancer gene 3 (PCA3) in urine, and the PHI is a diagnostic test that detects the level of prostate-specific antigen (PSA) in blood.

Online CME

Managing patients at risk of prostate cancer

After completing this module, you should know: How to advise men who are worried about prostate cancer, what information you should give them, and the treatment options available to men...

Prostate cancer: understanding the patient pathway and treatment options - in association with Prostate Cancer UK

After completing this module you should, regarding prostate cancer: Know what treatment options are available for each stage of the disease, be able to discuss the risks and benefits of...

Prostate cancer screening and the management of clinically localized disease

Learning outcomes: 1) Recognize who is at risk of prostate cancer; 2) Review the current recommendations on prostate cancer screening; 3) Recognize the harms associated with prostate cancer biopsy; 4)...

Clinical Trials

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Wed 01 Jul 2015

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected ...

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Thu 11 Jun 2015

The aim of this study is to investigate safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 for detection and localization of primary prostate cancer confirmed by ...

Back to top